Lower Cutoff Score for Oncotype DX Test May Be Needed for Male Breast Cancer Patients

NEW YORK – Recurrence scores from Genomic Health's Oncotype DX test might have a different meaning for men with breast cancer, suggesting a need for a lower cutoff score to predict mortality among male patients, a new study has found.